ATE347557T1 - Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung - Google Patents

Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung

Info

Publication number
ATE347557T1
ATE347557T1 AT01914191T AT01914191T ATE347557T1 AT E347557 T1 ATE347557 T1 AT E347557T1 AT 01914191 T AT01914191 T AT 01914191T AT 01914191 T AT01914191 T AT 01914191T AT E347557 T1 ATE347557 T1 AT E347557T1
Authority
AT
Austria
Prior art keywords
fluorisoquinoline
derivatives
production
pde
copd
Prior art date
Application number
AT01914191T
Other languages
English (en)
Inventor
Yasuhiko Kawano
Tatsumi Matsumoto
Osamu Uchikawa
Nobuhiro Fujii
Naoki Tarui
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE347557T1 publication Critical patent/ATE347557T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01914191T 2000-03-23 2001-03-22 Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung ATE347557T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000087121 2000-03-23

Publications (1)

Publication Number Publication Date
ATE347557T1 true ATE347557T1 (de) 2006-12-15

Family

ID=18603181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01914191T ATE347557T1 (de) 2000-03-23 2001-03-22 Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung

Country Status (7)

Country Link
US (1) US6924292B2 (de)
EP (1) EP1270577B1 (de)
AT (1) ATE347557T1 (de)
AU (1) AU2001239550A1 (de)
CA (1) CA2404226A1 (de)
DE (1) DE60125026T2 (de)
WO (1) WO2001070746A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DE10110772A1 (de) * 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
WO2003000697A1 (en) * 2001-06-22 2003-01-03 Takeda Chemical Industries, Ltd. Furoisoquinoline derivative, process for producing the same, and use
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
WO2003035650A1 (en) * 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Entry inhibitor
CN1681823A (zh) * 2002-07-26 2005-10-12 武田药品工业株式会社 呋喃并异喹啉衍生物及其用途
CA2495597A1 (en) * 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
RS20050117A (sr) * 2002-08-17 2007-06-04 Altana Pharma Ag., Novi benzonaftiridini
WO2004022536A1 (en) * 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
EA010408B1 (ru) 2002-10-23 2008-08-29 Гленмарк Фармасьютикалс Лтд. Трициклические соединения для лечения воспалительных и аллергических нарушений, способы их приготовления и содержащие их фармацевтические составы
OA13154A (en) 2003-04-11 2006-12-13 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them.
KR20060006954A (ko) 2003-04-30 2006-01-20 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 단백질 티로신 포스파타제-1b 억제제로서의 페닐 치환된카르복실산
US20050186276A1 (en) * 2003-07-17 2005-08-25 Pfizer Inc Pharmaceutical formulations
JP2007504201A (ja) * 2003-09-05 2007-03-01 アルタナ ファルマ アクチエンゲゼルシャフト 真性糖尿病の治療のためのpde4阻害剤の使用
PL2589599T4 (pl) 2004-03-03 2015-06-30 Takeda Gmbh Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
MX2007004400A (es) 2004-10-13 2007-06-19 Glenmark Pharmaceuticals Sa Procedimiento para la preparacion de n-(3,5-dicloropirid-a-il)-4- ifluorometoxi-8-metanosulfonamido-dibenzo [b,d] difuran-1-carboxamida.
BRPI0517211B8 (pt) 2004-12-17 2021-05-25 Glenmark Pharmaceuticals Sa composto, composição farmacêutica e seu uso.
US7943634B2 (en) 2004-12-17 2011-05-17 Glenmark Pharmaceuticals S.A. Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors
PL1856093T3 (pl) 2005-03-02 2010-05-31 Takeda Gmbh Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu
EP1874308A1 (de) 2005-03-08 2008-01-09 Nycomed GmbH Roflumilast zur behandlung von diabetes mellitus
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
US20070048388A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド 5ht受容体介在性の神経新生
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2009008531A (es) * 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
EP2100598A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP2100599A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
TW201431552A (zh) 2008-07-28 2014-08-16 Takeda Pharmaceutical 醫藥組成物
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2510928A1 (de) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
WO2018073110A1 (en) 2016-10-20 2018-04-26 Basf Se Quinoline compounds as fungicides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756105A (fr) * 1969-09-15 1971-03-15 Geigy Ag J R Nouveaux acides carboxyliques heterocycliques et medicaments contenant de tels acides
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
JPH07121933B2 (ja) * 1988-03-28 1995-12-25 キッセイ薬品工業株式会社 ジヒドロベンゾフラノン誘導体
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
ATE231501T1 (de) * 1995-05-18 2003-02-15 Altana Pharma Ag Phenyldihydrobenzofurane
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification

Also Published As

Publication number Publication date
DE60125026D1 (de) 2007-01-18
AU2001239550A1 (en) 2001-10-03
US20040092582A1 (en) 2004-05-13
DE60125026T2 (de) 2007-06-28
EP1270577A4 (de) 2003-09-17
EP1270577A1 (de) 2003-01-02
EP1270577B1 (de) 2006-12-06
CA2404226A1 (en) 2001-09-27
US6924292B2 (en) 2005-08-02
WO2001070746A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
ATE347557T1 (de) Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
WO2004024728A3 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
WO2004046112A3 (en) 3-amino-piperidine derivatives and processes for their preparation
NL300933I2 (nl) Letermovir
DK1444233T3 (da) A2B-adenosinreceptorantagonister
PT1252157E (pt) Carboxamidas de pirimidina uteis como inibidores de isozimas pde4
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
SE0200356D0 (sv) Novel use
CY1106969T1 (el) Αναστολεις dpp-iv
NO20064577L (no) Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander
WO2007009656A3 (de) Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung
SG179437A1 (en) Pyrimidine hydrazide compounds as pgds inhibitors
WO2001090071A3 (de) Substituierte iminoazine als herbizide
WO2006018718A3 (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
TW200500364A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
WO2004020430A3 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
RU2008129620A (ru) Пиразиноилгуанидиновые соединения, применяемые в лечении воспалительных или аллергических заболеваний
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
EP1465894A4 (de) Synthese und reinigung von valacyclovir
WO2005033066A3 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique sanofi-synthelabo
ATE296630T1 (de) Substituierte 8-arylchinoline als pde4-hemmer
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
WO2007010356A3 (en) Process for the preparation of sulfonamide derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties